LENZ Therapeutics, Inc. (LENZ) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US52635N1037
LENZ Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 19.09 m USD |
| Gross profit | 18.67 m USD |
| Operating income | -91.14 m USD |
| EBIT | -91.38 m USD |
| Net income | -82.13 m USD |
| Diluted EPS – continuing operations | -2.85 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
More stocks
- Sable Offshore Corp. (SOC)
- Wendell Industrial Co. Ltd (6761.TWO)
- Securitag Assembly Group Co Ltd (6417.TWO)
- Kangnam Jevisco Co Ltd (000860.KS)
- Prime Office A/S (PRIMOF.CO)
- Global Cord Blood Corporation (CORBF)
- Medinice S.A (ICE.WA)
- GEVORKYAN as (GEV.PR)
- Pine Cliff Energy Ltd (PNE.TO)
- Tai-Saw Technology Co Ltd (3221.TWO)
- Katahdin Bankshares Corp (KTHN)
- Maybank Securities (Thailand) PCL (MST.BK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.